Back to Search
Start Over
Factors associated with remission at 5-year follow-up in recent-onset axial spondyloarthritis: results from the DESIR cohort
- Source :
- Rheumatology, Rheumatology, Oxford University Press (OUP), 2022, 61 (4), pp.1487-1495. ⟨10.1093/rheumatology/keab565⟩
- Publication Year :
- 2021
- Publisher :
- Oxford University Press (OUP), 2021.
-
Abstract
- Objective The factors contributing to long-term remission in axial SpA (axSpA) are unclear. We aimed to characterize individuals with axSpA at the 5-year follow-up to identify baseline factors associated with remission. Methods We included all patients from the DESIR cohort (with recent-onset axSpA) with an available Ankylosing Spondylitis Disease Activity Score–CRP (ASDAS-CRP) at 5-year follow-up. Patients in remission (ASDAS-CRP Results Overall, 111/449 patients (25%) were in remission after 5 years. Among those never exposed to TNFi, 31% (77/247) were in remission compared with 17% (34/202) of those exposed to TNFi. Patients in remission after 5 years were more likely to be male, HLA-B27+, have a lower BMI, and a higher education level. Baseline factors associated with 5-year remission in patients never exposed to TNFi included lower BASDAI [adjusted odds ratio (ORa) 0.9, 95% CI: 0.8, 0.9) and history of peripheral arthritis (ORa 2.1, 95% CI: 1.2, 5.3). In those exposed to TNFi, remission was associated with higher education level (ORa 2.9, 95% CI: 1.6, 5.1), lower enthesitis index (ORa 0.8, 95% CI: 0.7, 0.9), lower BASDAI (ORa 0.9, 95% CI: 0.9, 0.9) and lower BMI (ORa 0.8, 95% CI: 0.7, 0.9). Conclusion This study highlights the difficulty in achieving 5-year remission in those with recent-onset axSpA, especially for the more active cases, despite the use of TNFi. Socio-economic factors and BMI are implicated in the outcome at 5 years.
- Subjects :
- Male
medicine.medical_specialty
MESH: Spondylarthritis
Logistic regression
Severity of Illness Index
remission
Rheumatology
MESH: Severity of Illness Index
Internal medicine
Spondylarthritis
medicine
Humans
Spondylitis, Ankylosing
Pharmacology (medical)
Mass index
prognostic factor
Recent onset
BASDAI
MESH: Treatment Outcome
[SDV.MHEP.RSOA] Life Sciences [q-bio]/Human health and pathology/Rhumatology and musculoskeletal system
Ankylosing spondylitis
MESH: Humans
business.industry
cohort
MESH: Axial Spondyloarthritis
MESH: Follow-Up Studies
Odds ratio
spondyloarthritis
MESH: Spondylitis, Ankylosing
medicine.disease
MESH: Male
Confidence interval
Treatment Outcome
[SDV.MHEP.RSOA]Life Sciences [q-bio]/Human health and pathology/Rhumatology and musculoskeletal system
Cohort
MESH: Tumor Necrosis Factor Inhibitors
Female
Tumor Necrosis Factor Inhibitors
business
MESH: Female
Axial Spondyloarthritis
Follow-Up Studies
Subjects
Details
- ISSN :
- 14620332, 14620324, and 14602172
- Volume :
- 61
- Database :
- OpenAIRE
- Journal :
- Rheumatology
- Accession number :
- edsair.doi.dedup.....1a8ed4818eeb5c4a91ea4e838a57cfc6